Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-4001 in androgenic alopecia
NCT02824380Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Jul 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DA-4001C in androgenetic alopecia (AGA) (2 arms), sponsored by Dong-A ST. Primary endpoints: Maximum steady state concentration of Finasteride at day 7, Area under the plasma concentration versus time curve of Finasteride at day 7 and 1 more. Started Jul 2016; status: completed.
02
Drugs
DA-4001C
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT02824380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02824380.